Lantern Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020
Market Capitalization	47	47	66	89	120
Market Cap Growth	80.25%	-29.06%	-26.55%	-25.41%	-
Enterprise Value	9	5	10	18	101
PE Ratio	-	-2.91	-4.60	-7.22	-20.26
PB Ratio	1.32	1.14	1.17	1.25	6.08
P/FCF Ratio	-6.91	-3.24	-5.13	-8.42	-21.12
P/OCF Ratio	-6.92	-3.24	-5.14	-8.43	-21.18
EV/EBITDA Ratio	-3.25	-0.35	-0.70	-1.45	-17.03
EV/EBIT Ratio	-3.21	-0.34	-0.69	-1.44	-17.02
EV/FCF Ratio	-4.12	-0.38	-0.77	-1.67	-17.74
Debt / Equity Ratio	0.01	0.01	0.00	0.00	0.01
Debt / EBITDA Ratio	-0.01	-0.01	0.00	-0.02	-0.02
Debt / FCF Ratio	-0.01	-0.02	0.00	-0.02	-0.02
Quick Ratio	9.70	15.42	19.92	30.83	34.81
Current Ratio	9.98	16.18	20.99	31.26	36.64
Return on Equity (ROE)	-41.20%	-34.10%	-23.60%	-16.00%	-36.30%
Return on Assets (ROA)	-38.40%	-32.20%	-22.30%	-15.60%	-34.00%
Return on Capital (ROIC)	-53.74%	-43.45%	-25.73%	-17.54%	-29.83%
Earnings Yield	-37.04%	-34.31%	-21.75%	-13.85%	-4.94%
FCF Yield	-28.88%	-30.88%	-19.51%	-11.88%	-4.74%
Buyback Yield / Dilution	1.05%	0.08%	0.50%	-153.31%	-117.61%
Total Shareholder Return	1.05%	0.08%	0.50%	-153.31%	-117.61%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).